CYTOMED THERAPEUTICS LTD (GDTC) Stock Income Statement
USA - NASDAQ:GDTC - SGXZ17669631 - Common Stock
1.88 USD
-0.16 (-7.84%)
1.84 USD
-0.04 (-2.13%)
| TTM (2024-6-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | 200 | 300 | 0 | 0 | 0 | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 3.60M | 3.94M | 2.95M | 1.72M | 1.85M | |||
| Research and Development | 1.51M | 1.31M | 1.24M | 860.00K | 830.00K | |||
| Selling, General, and Administrative Expenses | 2.07M | 2.65M | 680.00K | 660.00K | 250.00K | |||
| Operating Income | -3.60M | -3.94M | -2.95M | -1.72M | -1.85M | |||
| Interest Income/Expense | 537.10K | -190.90K | -180.00K | -340.00K | -110.00K | |||
| Other Income/Expense | null | null | null | null | null | |||
| Non Recurring Items | null | 0 | 0 | 10.00K | 20.00K | |||
| Income Before Taxes | -3.06M | -4.13M | -3.13M | -2.05M | -1.94M | |||
| Income Tax | 700 | 700 | 0 | 0 | 0 | |||
| Net Income | -3.06M | -4.13M | -3.13M | -2.05M | -1.94M | |||
| EBITDA | -3.25M | -3.56M | -2.56M | -1.39M | -1.56M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.26539999999999997 | -0.3888 | -0.27 | -0.19 | -0.18 | |||
| Non GAAP EPS | null | null | null | null | null | |||
| Statistics | ||||||||
All data in SGD